TRAC and graft versus host disease: These cells are named for their invariant TCRα chain that does not promote GVHD, but instead facilitates TCR-mediated targeting of CD1-expressing cells, as well as enabling clinically useful expansion through CD1-expressing antigen-presenting cells incubated with α-galactosyl ceramide glycolipid [73].